

Conservation of polyamine regulation by translational frameshifting from yeast to mammals

Ivaylo P.Ivanov, Senya Matsufuji¹,
Yasuko Murakami¹, Raymond F.Gesteland
and John F.Atkins²

Department of Human Genetics, University of Utah, 2030 E 15N,
Salt Lake City, UT 84112-5330, USA and ¹Department of
Biochemistry II, Jikei University School of Medicine, Minato-ku,
Tokyo 105-8461, Japan

²Corresponding author
e-mail: john.atkins@genetics.utah.edu

Regulation of ornithine decarboxylase in vertebrates involves a negative feedback mechanism requiring the protein antizyme. Here we show that a similar mechanism exists in the fission yeast *Schizosaccharomyces pombe*. The expression of mammalian antizyme genes requires a specific +1 translational frameshift. The efficiency of the frameshift event reflects cellular polyamine levels creating the autoregulatory feedback loop. As shown here, the yeast antizyme gene and several newly identified antizyme genes from different nematodes also require a ribosomal frameshift event for their expression. Twelve nucleotides around the frameshift site are identical between *S.pombe* and the mammalian counterparts. The core element for this frameshifting is likely to have been present in the last common ancestor of yeast, nematodes and mammals.

Keywords: antizyme/frameshifting/polyamines/yeast

Introduction

The efficiency of +1 ribosomal frameshifting at a specific codon is used as a sensor to regulate polyamine levels in mammalian cells. The frameshifting occurs in decoding the gene antizyme 1, which has two partially overlapping open reading frames (ORFs). Protein sequencing showed that the reading-frame shift occurs at the last codon of ORF1, causing a proportion of ribosomes to enter ORF2 to synthesize a transframe protein (Matsufuji *et al.*, 1995). ORF2 encodes the main functional domains (Matsufuji *et al.*, 1990; Miyazaki *et al.*, 1992) of antizyme but has no ribosome initiation site of its own. The antizyme 1 protein binds to ornithine decarboxylase (ODC) (Murakami *et al.*, 1992a; Li and Coffino, 1993, 1994), inhibits it (Heller *et al.*, 1976) and targets it for degradation by the 26S proteasome without ubiquitylation (Murakami *et al.*, 1992b, 1999). ODC catalyzes the first and usually rate-limiting step in the synthesis of polyamines, conversion of ornithine to putrescine. Putrescine is a substrate for the synthesis of spermidine and spermine. Because of its inhibition of ODC, antizyme 1 is a negative regulator of the synthesis of polyamines. In addition, antizyme 1 is a negative regulator of the polyamine transporter (Mitchell *et al.*, 1994; Suzuki *et al.*, 1994; Sakata *et al.*, 1997). As

discovered by Matsufuji and colleagues (Gesteland *et al.*, 1992) and Rom and Kahana (1994), increasing polyamine levels elevate frameshifting in decoding antizyme 1 mRNA and so increase the level of antizyme 1. Since antizyme 1 negatively regulates the synthesis and uptake of polyamines, the frameshifting is the sensor for an autoregulatory circuit. A second mammalian paralog of antizyme, antizyme 2, has very similar properties to antizyme 1, including the regulatory frameshifting, but does not stimulate degradation of ODC under certain conditions where antizyme 1 is active (Ivanov *et al.*, 1998a; Zhu *et al.*, 1999; Y.Murakami, S.Matsufuji, I.P.Ivanov, R.F.Gesteland and J.F.Atkins, in preparation). Just like antizyme 1, antizyme 2 mRNA is ubiquitously expressed in the body but is 16 times less abundant than mRNA of antizyme 1 (Ivanov *et al.*, 1998a). In addition to antizyme 1 and 2, mammals have a third paralog of the gene, antizyme 3 (also encoded by two ORFs), which is expressed only during spermatogenesis (Ivanov *et al.*, 2000). Zebrafish also have multiple antizyme genes, which differ in their expression patterns and activities (Saito *et al.*, 2000).

Numerous studies have addressed the regulation of fungal ODC in response to exogenously added polyamines. In the cases examined, *Physarum polycephalum* (Mitchell and Wilson, 1983), *Saccharomyces cerevisiae* (Fonzi, 1989; Toth and Coffino, 1999) and *Neurospora crassa* (Barnett *et al.*, 1988; Williams *et al.*, 1992), added polyamines, especially spermidine, result in significant repression of ODC activity. The mechanisms of repression seem to vary from fungus to fungus and are apparently different from the mechanism of polyamine-dependent regulation of ODC in higher eukaryotes. In some cases, the existence of an antizyme-like protein has been suggested but has either been disproved, as in the case of *N.crassa* (Barnett *et al.*, 1988), or has never been substantiated, as in the case with *S.cerevisiae*.

As expected from their small cationic nature and ability to neutralize negative charges locally, polyamines play key roles in processes ranging from the functioning of certain ion channels (Williams, 1997), nucleic acid packaging, DNA replication, apoptosis, transcription and translation. The role of polyamines can be complex as illustrated by the transfer of the butylamine moiety of spermidine to a lysine residue to form hypusine in mammalian translation initiation factor eIF-5A, the only known substrate for this reaction (Tome *et al.*, 1997; Lee *et al.*, 1999). Spermine negatively regulates the growth of prostatic carcinoma cells at their primary site (Smith *et al.*, 1995), but at later stages of tumor progression it fails to induce antizyme, which correlates with cells becoming refractory to spermine (Koike *et al.*, 1999). Lack of antizyme function is also important in the early de-regulation of cellular proliferation in oral tumors (Tsuji

et al., 1998) and probably others. The levels of polyamines are altered in many tumors, and inhibitors of polyamine synthesis are being tested for antiproliferative and cell death effects. The synthesis of ODC varies during the cell cycle in normal cells (Linden *et al.*, 1985; Fredlund *et al.*, 1995). It is induced by many growth stimuli and is constitutively elevated in transformed cells (Pegg, 1988; Auvinen *et al.*, 1992) with some phosphorylated ODC being translocated to the surface membrane where it is important for mitotic cytoskeleton rearrangement events (Heiskala *et al.*, 1999).

Antizyme is one example of certain mRNA-contained signals that can elevate specific frameshifting >1000-fold above the background level of normal translational errors. In addition to antizyme, frameshifting is also involved in the decoding of some bacterial and yeast genes and especially in many mammalian Retroviruses and Coronaviruses, plant viruses and bacterial insertion sequences (Atkins *et al.*, 1999). The site of frameshifting in both mammalian antizyme 1 and 2 mRNAs is UCC UGA, where quadruplet translocation occurs at UCCU (underlined) to shift reading to the +1 frame, immediately before the UGA stop codon of the initiating frame (Matsufuji *et al.*, 1995; Ivanov *et al.*, 1998a). For the frameshifting to occur with an efficiency of 20% or more, it is important that the 3' base of the quadruplet is the first base of a stop codon. Other important features are a pseudoknot just 3' of the shift site and a specific sequence 5' of the shift site (Matsufuji *et al.*, 1995; Ivanov *et al.*, 1998a). A pseudoknot 3' of the shift site is a common stimulator for eukaryotic -1 frameshifting, but the synthesis of antizyme is the only known case utilizing +1 frameshifting.

Comparative analysis of RNA sequences from different organisms is informative about important features and the different options selected by evolution. Since most of the known examples of programmed frameshifting are in viruses or chromosomal mobile elements, the opportunity for comparison of frameshift cassettes in divergent organisms where the time of divergence can be approximated is limited. A start has been made with the frameshifting required for bacterial release factor 2 expression (Persson and Atkins, 1998), but antizyme provides the first opportunity for such a comparison in eukaryotes. Antizyme genes in genetically tractable lower eukaryotes would be helpful for understanding the functionally important interactions responsible for autoregulatory programmed frameshifting.

Results

Identification of an antizyme gene in *Schizosaccharomyces pombe*

A search for DNA sequences encoding protein sequences homologous to *Drosophila melanogaster* antizyme (Ivanov *et al.*, 1998b) and *Homo sapiens* antizyme 1 identified the same *S.pombe* anonymous cDNA clone (DDBJ/EMBL/GenBank accession No. D89228). The similarity is limited (~10% identity, 24% similarity to both human antizyme 1 and *D.melanogaster* antizyme); however, it is highest in regions that are most highly conserved among the previously identified antizymes (Figure 1A). Closer examination of the cDNA nucleotide


sequence provided further evidence that it encodes an *S.pombe* homolog of antizyme. The initiating AUG codon for the ORF that is similar to higher eukaryotic antizymes (ORF2 of those genes) is not the 5'-most AUG in this cDNA. In fact, there are eight AUGs closer to the 5' end. The first or the second AUGs would initiate translation of an ORF (ORF1) that overlaps the longer downstream ORF (ORF2) such that a +1 translational frameshifting event in the overlap would generate a protein product analogous to the products of antizyme genes from higher eukaryotes. Furthermore, the last 12 nucleotides of ORF1 (UGG-UGC-UCC-UGA) are identical to the last 12 nucleotides of mammalian antizyme 1 ORF1s, including the frameshift site. Eleven of these 12 nucleotides are identical to the corresponding regions of all previously identified antizyme genes (Figure 1B). Previous experiments with the mammalian frameshift sequence tested in *S.pombe* have shown that this short 12 nucleotide sequence, by itself, is sufficient to stimulate measurable levels (up to 0.5%) of +1 frameshifting (Ivanov *et al.*, 1998c). To confirm the ORF configuration of the putative *S.pombe* antizyme gene, a region corresponding to the two overlapping ORFs plus ~80 nucleotides of the 5' UTR and 370 nucleotides of the 3' UTR, was amplified from both *S.pombe* genomic DNA and a cDNA library. The sequence of the amplified DNA confirmed that there are indeed two overlapping ORFs with the deduced configuration. This sequence (DDBJ/EMBL/GenBank accession No. AF217277) differs from the previously sequenced cDNA clone by three nucleotides (two in the coding region and one in the 3' UTR); one changes an alanine codon to proline, another is a silent mutation within a proline codon. Since the sequences from the cDNA library and genomic DNA are identical, we conclude that the differences with clone No. D89228 are most likely due to strain variation. This gene contains no introns within the amplified region.

The *S.pombe* protein was tested for antizyme activity using a gene fusion with glutathione *S*-transferase (*GST*). In this construct, ORF1 and ORF2 of antizyme are fused in-frame by deleting the T nucleotide that encodes U of the stop codon of ORF1. This *GST*-antizyme fusion gene was expressed in *Escherichia coli* and the protein was purified by affinity chromatography. ODC inhibitory activity was tested by incubating the recombinant antizyme protein with an *S.pombe* crude extract and then assaying the mixture for ODC activity. The results (Figure 2) show that the recombinant protein can inhibit *S.pombe* ODC. *GST* alone (1 µg) does not inhibit *S.pombe* ODC (data not shown). In light of these results, the *S.pombe* gene will be called *S.pombe* ODC antizyme (*SPA*). Interestingly, the *S.pombe* ODC was also inhibited by mouse antizyme 1 and antizyme 2 (both expressed as *GST* fusions); however, the yeast fusion protein did not inhibit mouse ODC (data not shown).


Deletion and overexpression of *SPA*

Although the effects of overexpression of antizyme on cellular physiology have been tested previously in mammalian cells, the physiological changes associated with complete absence of antizyme activity have not yet been investigated because of the complication of multiple antizymes. The single *S.pombe* antizyme provides the chance to explore a knockout. *SPA* deletion strains were

A



F-S SITE



B




Fig. 1. Sequence comparison of different antizyme genes. (A) Amino acid comparison. Black background indicates amino acid identity among at least eight proteins. Shaded background indicates amino acid similarity among at least eight proteins. An arrow indicates the position of the frameshift site and the two most highly conserved regions are underlined. (B) Nucleotide sequence comparison of the frameshift sites. Black background indicates nucleotide identity among at least eight antizyme genes. The frameshift site is indicated. The stems of the vertebrate antizyme 3' RNA pseudoknot and the 'core' sequence are underlined (PKS1 = vertebrate antizyme RNA pseudoknot stem 1; PKS2 = stem 2 of the same pseudoknot). Species abbreviations are as follows: *S.p.*, *Schizosaccharomyces pombe*; *C.e.*, *Caenorhabditis elegans*; *H.c.*, *Haemonchus contortus*; *N.a.*, *Necator americanus*; *P.p.*, *Pristioncus pacificus*; *O.v.*, *Onchocerca volvulus*; *D.m.*, *Drosophila melanogaster*; *D.r.*, *Danio rerio*; *X.l.*, *Xenopus laevis*; *G.g.*, *Gallus gallus*; *M.m.*, *Mus musculus*; *H.s.*, *Homo sapiens*.

generated by replacing the two ORFs of the gene with the ORFs of either *URA4* or *LEU2* (see Materials and methods). Complete deletion of *SPA* (both ORFs) did not affect the viability of *S.pombe* cells in rich (YE) or minimal (MM) media. Temperature had no differential effect on mutant and wild-type cell growth. Similarly, the growth rates, mating efficiencies and overall morphology of the knockout strains are apparently indistinguishable from those of wild-type cells (results not shown).

In wild-type *S.pombe* cells the most abundant polyamine is spermidine followed by putrescine (Figure 3). Spermine and cadaverine are found in much smaller amounts. This distribution of polyamine content is very similar to that in other fungi for which polyamine concentrations have been measured (for references, see review by Tabor and Tabor, 1985). The effect of *SPA* deletion on cellular polyamine contents was examined in both exponentially growing and stationary phase cells

(Figure 3). The cellular concentrations of putrescine, spermidine and cadaverine (but not spermine) were higher in the knockout strains than in wild-type cells. The greatest effect was seen on putrescine and cadaverine content, with smaller effects on spermidine, presumably because eukaryotic ODC activity directly catalyzes decarboxylation of both ornithine and lysine to produce putrescine and cadaverine, respectively (Pegg and McGill, 1979), but subsequent regulatory events affect homeostasis of spermidine and spermine. The effect of inactivating antizyme on the polyamine contents in exponentially growing cells is modest (<2-fold in all cases). The effect becomes very pronounced in cells in stationary phase with up to 40- and 10-fold increases of putrescine and cadaverine contents, respectively, in the knockout strains.

To test overexpression of *SPA*, two versions of the gene were cloned into pREP3 expression vector behind a strong, thiamine-repressible promoter (nmt1). One had the wild-




Fig. 2. Inhibition of *S.pombe* ODC by SPA. Various amounts of affinity-purified GST-SPA were mixed with *S.pombe* ODC-active extract and assayed for ODC activity.




Fig. 3. Polyamine contents of SPA^+ and Δspa strains in logarithmic growth or stationary phase in MM media.

type *SPA* sequence while in the second, ORF1 and ORF2 are fused in-frame. *SPA* wild type and an *SPA* deletion strain were transformed with each of the overexpression constructs. Derepression of the *nmt1* promoter is a gradual process since it requires dilution of the intracellular pool of thiamine (the repressor) through cell division. After 2.5 days of exponential growth under derepressed conditions, yeast strains transformed with either *SPA* overexpression construct show significant increases in doubling time (Figure 4A). The growth inhibition is greater with the construct expressing the in-frame version of *SPA* and after prolonged incubation (5–7 days); these cells cease growth and accumulate in G_1 as determined by flow cytometry (data not shown). The fact that the in-frame overexpression construct, which differs by a single nucleotide from the wild-type construct, confers a more severe phenotype is consistent with the hypothesis that translational frameshifting is required for expression of *SPA*. The growth phenotype associated with *SPA* overexpression is only partially relieved by adding 100 μM putrescine to the media (1 mM had no further effect) (data not shown). To see whether the slower growth is correlated with aberrant polyamine levels the polyamine contents of the deletion strain carrying in-frame *SPA* overexpression vector were measured under derepressed and repressed conditions, in both cases after 2 days of exponential growth (Figure 4B). As expected, overexpression of *SPA* results in significant reduction in the intracellular levels of all four polyamines. After longer (4–5 days) incubation under derepressed conditions, no putrescine and cadaverine can be detected (data not shown).

Translational frameshifting during expression of *SPA*

Previously, we developed an assay for measuring antizyme translational frameshifting in both *S.cerevisiae* (Matsufuji *et al.*, 1996) and *S.pombe* (Ivanov *et al.*, 1998c). Briefly, the nucleotide sequence to be assayed is inserted between *GST* and *lacZ*, such that ORF1 of the assayed sequence is fused in-frame to *GST*, while ORF2 is fused in-frame to *lacZ*. β -galactosidase activity provides a measure of frameshifting efficiency. To determine whether translational frameshifting occurs in the overlap of ORF1 and ORF2 of *SPA*, a region of *SPA* including all but the first codon of ORF1 plus 180 nucleotides downstream of the ORF1 stop codon was tested. +1 frameshifting occurred at 2.2% compared with a construct in which ORF1 and ORF2 are fused in-frame. This result is consistent with +1 frameshifting being crucial for expression of *SPA*.

Previous experiments have shown that the frameshift cassette of mammalian antizyme 1 can direct efficient +1 frameshifting when tested in *S.pombe*. The reverse experiment was conducted here. The *SPA* gene was translated *in vitro* in rabbit reticulocyte lysate and its resulting frameshift efficiency measured. With no addition of polyamines, frameshifting efficiency is ~1.5%. Addition of spermidine to the translation mixture to a final concentration of 1 mM results in a 3.7-fold increase in frameshifting to ~5.5%, a level even higher than that observed in the endogenous system *in vivo* (autoradiogram not shown).




Fig. 4. Effects of SPA overexpression [with wild type (*SPA* WT) or in-frame (*SPA* IF) constructs] on cell growth of $\Delta spa::URA4$ and SPA^+ strains (A) and cellular polyamine contents of $\Delta spa::URA4$ strain overexpressing *SPA* IF construct (B) (all in MM media).

The observed efficiency of frameshifting with the *SPA* frameshifting cassette *in vivo* in *S.pombe* is significantly more than that expected from its limited nucleotide similarity to the antizyme frameshift sites of higher eukaryotes. This prompted a search for additional stimulatory elements within the *SPA* frameshift cassette. The following experiments were done in a strain carrying deletion of *SPA* (high polyamines) because it gives higher frameshifting and higher β -galactosidase activity in general; however, we obtained similar ratios for mutant to

wild-type frameshifting efficiency in a strain with the intact *SPA* gene. Deleting 5' sequences up to the third to last sense codon of ORF1 has little or no effect on frameshifting efficiency. Deleting all but the last sense codon (UCC) of ORF1 leads to a 4- to 5-fold reduction in frameshifting efficiency (Figure 5A). This implies that the conservation of the six nucleotides 5' of the UCC-UGA frameshift site is due to their importance for stimulating +1 frameshifting. It also suggests that no additional ORF1 sequences of *SPA* stimulate the +1 recoding event. The 180 nucleotide 3' region was searched for possible structure by computer RNA folding algorithms plus visual inspection. The algorithms predicted several minimal structures in that region. 3' deletion constructs (constructs del.3,3'-81,3') tested the importance of any putative structure on the frameshifting efficiency. The results (Figure 5B and C) show that all of these deletions lead to a significant (~10-fold) reduction in +1 frameshifting, indicating the presence of a major 3' stimulatory element in the 180 nucleotide region immediately following the frameshift site of *SPA*. However, the results indicate that none of the putative RNA structures in this region are sufficient for the activity of this element. Several additional 3' deletions delineated the boundaries of this stimulatory element from the frameshift site to 150 and 180 nucleotides downstream (since construct del.150,3' stimulates 5.5-fold more +1 frameshifting than del.129,3', 150 nucleotides downstream probably contain most of the 3' stimulator).

In the experiments described above, two of the characteristics of the autoregulatory circuit of mammalian antizyme 1 were confirmed: *SPA* inhibition of ODC and the +1 translational frameshifting. The key question left is whether the recoding event is responsive to polyamine levels in cells. As shown above, overexpression of *SPA* leads to significant reduction of polyamine levels in *S.pombe*. An SPA^+ strain was co-transformed with an *SPA* wild-type overexpressing plasmid (cells overexpressing wild-type *SPA* grow slowly but continuously) and a construct that monitors the +1 frameshifting from an *SPA* frameshift sequence. The +1 frameshifting was compared with that in *SPA* non-overexpressing cells (in both cases frameshifting was measured relative to in-frame control). The results (Figure 6) show a significant reduction (6.5-fold) in frameshifting efficiency in *SPA*-overproducing cells that correlates with a decrease of polyamine content (4.5-fold for putrescine and 3.9-fold for spermidine). This indicates that polyamines modulate the frameshifting efficiency of *SPA*. An alternative but less likely possibility is that *SPA* overexpression reduces frameshifting because high levels of *SPA* transcript titrate some factor limiting for frameshifting.

The *SPA* frameshift signals direct 2-fold more frameshifting in $\Delta spa::LEU2$ cells (4.4%) than in SPA^+ cells (in both cases the measurement is done during stationary phase); however, the relatively high standard deviations for both measurements make it difficult to draw firm conclusions from this particular result.

Identification of antizyme genes in nematodes

A search of *Caenorhabditis elegans* expressed sequence tag (EST) sequences with mammalian antizyme 1 sequence identified 20 clones. These sequences could be




Fig. 5. Effects of 5' and 3' deletions (relative to the frameshift site) on the +1 frameshifting efficiency of *SPA*. The constructs were transformed in $\Delta spa::LEU2\ ura4-D18\ leu1-32\ ade6-M216\ h^+$ strain (high polyamine levels). (A) 5' deletion data. Numbers on the x-axis indicate *SPA* ORF1 sense codons left [wild type (WT) = 66 codons left]. (B) 3' deletion data. x-axis numbers indicate nucleotides left 3' of the frameshift site (WT = 180 nucleotides left). * marks constructs for which in-frames were not made. In these cases frameshifting was calculated relative to the closest available in-frame construct. (C) Graphical representation of the deletion data in which the deletions are shown to scale relative to the coding region of *SPA* (ORF1 + ORF2). The position and size of the WT standard is also depicted. The frameshift site is indicated by an arrow.

deconvoluted into a contiguous cDNA sequence. Primers designed on the basis of this sequence were used to PCR amplify and subclone this cDNA from a *C.elegans* cDNA library. The sequence of the subcloned cDNA was confirmed (DDBJ/EMBL/GenBank accession No. AF217278); the subsequently released genomic sequence of this *C.elegans* gene (DDBJ/EMBL/GenBank accession No. AF040659) confirms our cDNA data. The amino acid sequence deduced from the cDNA sequence revealed that the longer ORF has similarity to previously reported antizyme sequences (overall 27% identity, 39% similarity to human antizyme 1; 19% identity, 34% similarity to *Drosophila* antizyme). These similarities are higher than that of *SPA* to these two antizyme genes and again are concentrated in the regions most highly conserved among previously identified antizymes (Figure 1A). Just like mammalian antizymes, the longer ORF (ORF2) lacks an appropriate in-frame initiation codon, and expression could be provided by initiation in a short upstream overlapping ORF (ORF1) leading to +1 ribosomal frameshifting in the overlap. The putative *C.elegans* antizyme frameshift site (the nucleotides proximal to the end of ORF1) has 18 of 26 nucleotides identical to the consensus sequence for antizyme frameshift sites (Figure 1B).

Frameshifting for expression of *C.elegans* antizyme was investigated in heterologous systems. Two constructs containing the entire antizyme cDNA, one with the wild-type sequence and one with a single nucleotide deletion that fuses ORF1 to ORF2 in-frame (in-frame control), were transcribed *in vitro* and the RNA was translated in rabbit reticulocyte lysate. The products were examined by SDS-PAGE (Figure 7). The main product from both constructs has an apparent M_r of 21 kDa, slightly greater than the predicted M_r of 17.7 kDa [aberrant, slower than expected, mobility is observed with antizyme proteins from other species (Ivanov *et al.*, 1998a)]. From the ratio of wild-type to in-frame product, we estimate that the efficiency of frameshifting of *C.elegans* antizyme in reticulocyte lysate is ~0.8%, which is somewhat lower than *SPA* frameshifting in the same system. Addition of spermidine to the translation reactions almost doubles the efficiency of frameshifting to ~1.5% (the exact numbers are not easy to determine because of difficulty in defining background values). The frameshifting properties of *C.elegans* antizyme mRNA were also tested *in vivo* in *S.pombe* cells. A sequence including all but the first codon of ORF1 plus 180 nucleotides downstream was inserted between *GST* and *lacZ* of the PIU-LAC plasmid. Comparison of the β -galactosidase activity of cells




Fig. 6. Effect of polyamine depletion on *SPA* +1 frameshifting. Polyamine depletion is achieved by overexpression of the wild-type version of *SPA*. The same cultures were assayed both for frameshifting and polyamine content. Numbers above columns indicate fold reduction of frameshifting and polyamine content compared with cells that do not overexpress *SPA*.




Fig. 7. Frameshifting of *C.elegans* antizyme (AZ) mRNA in reticulocyte lysates. Translation products were separated on a 17.5% SDS-PAGE gel. Normally *in vitro* translation reactions contain 0.5 mM spermidine ('-', 0.5 mM and '+', 1.0 mM spermidine). IFC, in-frame control.

($\Delta spa::LEU2$ strain) transformed with the wild-type construct and the in-frame control constructs indicated 3.5% +1 frameshifting. From the frameshifting observed in the heterologous systems, as well as the sequence considerations discussed above, we conclude that expression of this *C.elegans* gene requires ribosomal frameshifting.

Searching the EST database with the newly discovered *C.elegans* antizyme identified antizyme orthologs in four other nematode species. In two cases (*Necator americanus* and *Haemonchus contortus*), the cDNA sequences in the database were sufficient to make contigs of the complete coding regions. In the other two cases [*Onchocerca volvulus* (DDBJ/EMBL/GenBank accession No. AF217279) and *Pristioncus pacificus* (DDBJ/EMBL/

GenBank accession No. AF217280)] the complete cDNA sequences were obtained by PCR amplifying and sequencing the full genes from cDNA libraries. As with the previously identified eukaryotic antizyme genes, the ORF configuration of the newly found nematode orthologs implies the necessity for +1 frameshifting for synthesis of full-length protein.

The *C.elegans* antizyme mRNA frameshift site UUU-UGA is unique, differing from the UCC-UGA of previously known antizyme mRNAs. The *C.elegans* antizyme gene shares this feature with *N.americanus* and *H.contortus* but not with *P.pacificus* and *O.volvulus* antizymes. The phylogenetic tree of nematode antizyme protein sequences matches exactly the phylogenetic relationship (Blaxter, 1998) of the nematodes expressing them, indicating that these gene sequences are the result of divergent evolution within the nematode lineage (data not shown). These results also show that the UUU-UGA frameshift site evolved after the last common ancestor of *P.pacificus* and *C.elegans* but before the divergence of *C.elegans*, *N.americanus* and *H.contortus* (probably 450–500 million years ago).

The ability of UUU-UGA sequence to direct +1 frameshifting was further tested in a mammalian system in the context of the mammalian antizyme mRNA (i.e. in the presence of the 3' RNA pseudoknot and 5' stimulator). A BMV-coat-protein-antizyme 1 gene fusion construct, which has a TCC-TGA to TTT-TGA substitution, was transcribed and then translated in a rabbit reticulocyte lysate. Eleven percent frameshift efficiency was seen in the absence of exogenously added polyamines, 2.2 times the efficiency seen with the UCC-UGA transcript. The frameshift efficiency becomes 18% when 0.6 mM spermidine is added, which is 1.3 times that with the wild type (Matsufuji *et al.*, 1995). Similar results were obtained in cultured mammalian (Cos7) cells transfected with TTT-TGA mutant construct, the frameshift being higher than that of wild-type construct in both high- and low-polyamine conditions (our unpublished results). These results demonstrate that the putative *C.elegans* frameshift site (UUU-UGA) is, if anything, shiftier than UCC-UGA in the antizyme 1 context and is subject to polyamine stimulation.

Discussion

The results presented show that the yeast *S.pombe* has a homolog of mammalian antizyme. This is the first documented example of antizyme-type regulation of ODC in a lower eukaryote.

Deleting *SPA* from the yeast genome has no detectable effect on viability or any other overt phenotypic effect but, as expected, it results in altered accumulation of polyamines in the cell. Interestingly, the effect is most pronounced in cells in stationary phase, where the knockout cells accumulate up to 40 times more putrescine than wild-type counterparts. This compares with a <2-fold increase of putrescine in exponentially growing cells. A likely explanation for this observation is that the usual rate of ornithine decarboxylation in exponentially growing cells is close to capacity given 'normal' concentrations of substrate, enzyme and product. At the same time, all newly synthesized polyamines are continuously diluted through

cell growth and division at a rate that is almost identical to the rate of maximum capacity synthesis. Cells in stationary phase can no longer dilute newly synthesized polyamines, and more importantly lack an effective antizyme-independent mechanism of shutting off ODC. This suggests that SPA is the primary regulator of ODC activity in *S.pombe*, not only during cell growth (short term regulation) but also in non-dividing cells (longer term regulation).

Overexpression of SPA (5–7 days derepression) leads to complete depletion of intracellular putrescine. This result implies that in *S.pombe* ornithine decarboxylation is the only source of putrescine synthesis (the pathway from arginine via agmatine is not utilized). The complete depletion of cadaverine in SPA overexpressing cells suggests that ODC is the only enzyme in *S.pombe* that can decarboxylate lysine, which is also the case in rat tissues (Pegg and McGill, 1979).

It is somewhat perplexing that addition of putrescine to the media leads to only partial relief of the growth phenotype associated with SPA overexpression. There are two likely explanations. (i) Perhaps *S.pombe* imports putrescine poorly. (ii) Alternatively, like the mammalian system, maybe SPA inhibits not only ODC but also the polyamine transporter. Further experiments will help to distinguish between these two models.

It is unclear how widespread the antizyme gene is within the fungal kingdom. We have identified and cloned antizyme homologs from two other fission yeasts (*Schizosaccharomyces octosporus* and *Schizosaccharomyces japonicus*) and from two distantly related fungi (*Botryotinia fuckeliana* and *Emericella nidulans*) (our unpublished results). The antizyme frameshift site of the latter two fungi has evolved in a unique way different from all other known antizymes, but nevertheless even these two distantly related fungi have conserved the autoregulatory +1 frameshifting. The fact that the yeast *S.pombe* has an antizyme gene suggests the possibility that the higher eukaryotic metazoans may all have an antizyme gene.

The only previously reported antizyme activity in unicellular organisms is from *E.coli*, but recent analyses suggest that *E.coli* does not have a true antizyme (Ivanov *et al.*, 1998d). This makes SPA the first bona fide antizyme in a unicellular organism.

The remarkable similarity of the core sequence important for antizyme frameshifting from *S.pombe* to humans could be due to convergent or divergent evolution. The near identity of this sequence in worms, *Drosophila*, *Xenopus*, zebrafish and humans argues against convergent evolution, as if antizyme frameshifting arose in a common ancestor perhaps more than one billion years ago.

Three *cis*-acting RNA elements are known to stimulate mammalian antizyme 1 frameshifting. One is a 50 nucleotide sequence immediately 5' of the shift site (Matsufuji *et al.*, 1995; our unpublished results). A second stimulator is the UGA stop codon of ORF1 and the third is an RNA pseudoknot starting 3 nucleotides 3' of the UGA stop codon. Among frameshift sites of the previously identified antizymes from mammals all the way to *Drosophila*, there is substantial similarity in the sequences immediately 5' of the shift site. Sixteen of the last 18 nucleotides of ORF1 are completely conserved in these

genes. *Schizosaccharomyces pombe* and *C.elegans* antizymes have 9 of 9 and 6 of 9 (14 out of 19 in *O.volvulus*) nucleotides identical to the consensus, respectively. For the 5' sequences, generally, the more distantly related two antizymes are, the more the similarity is confined to the 3' end of that region. Our SPA ORF1 deletion data show that mutation of nucleotides that are part of the 5' consensus sequence leads to reduced frameshifting efficiency. This is another indication that conservation of nucleotide sequence in this region is because of its importance for stimulating efficient +1 frameshifting. It is quite striking that in all antizyme gene sequences identified so far, including a number of unpublished ones, ORF1 ends with a UGA stop codon. This is particularly surprising since any of the other two stop codons can substitute for UGA to stimulate antizyme 1 frameshifting, although slightly less efficiently, *in vitro* (Matsufuji *et al.*, 1995) and *in vivo* (our unpublished results).

The 3' pseudoknot that stimulates frameshifting in antizyme 1 is highly conserved in all known vertebrate antizymes, including mammalian antizyme 2 (Figure 1B). None of the invertebrate antizyme mRNAs identified so far, including those presented here, has a sequence in the equivalent region that can be simply folded to a comparable RNA structure. However, sequences immediately 3' of the frameshift site are conserved between invertebrates and vertebrates. The conservation of this region between *Drosophila* and the vertebrate counterparts has already been noted (Ivanov *et al.*, 1998b). The *C.elegans* antizyme gene contains the sequence YGYCCCYCA (Y = pyrimidine) in this region, which is identical to the consensus. The antizyme genes from the other four nematodes also have a similar sequence (Figure 1B). The significance of this similarity is not clear [in fact, sequences in this region appear to play no role in antizyme 1 *in vitro* frameshifting outside of the RNA pseudoknot context (Matsufuji *et al.*, 1995)].

Only two examples are known where RNA elements 3' of the frameshift site stimulate +1 frameshifting. One is the RNA pseudoknot of mammalian antizyme 1 and the second is a short RNA sequence immediately following the frameshift site of Ty3 (Farabaugh *et al.*, 1993). Additional examples would be very helpful in deciphering the role such elements play in the mechanism of +1 frameshifting. It is currently not known how many and which of the invertebrate antizyme genes contain 3' frameshift stimulators. The results presented here show that an *S.pombe* 3' stimulator enhances frameshifting ~10-fold. This stimulator appears completely different from the 3' RNA pseudoknot in vertebrates. Our deletion experiments indicate that none of the predicted RNA structures contained within the minimally required 3' region [up to 150–180 nucleotides downstream of the frameshift site (Figure 5C)] are sufficient to confer the stimulatory effect. The SPA 3' stimulator may act directly through sequence or may have an unusual RNA structure involving non-Watson–Crick base pairing. More detailed mutagenesis combined with phylogenetic analysis would be required to discern the nature of the 3' stimulator of SPA.

The nematode antizymes were analyzed for the presence of possible 5' or 3' stimulators flanking the core frameshift site. Computer RNA folding programs did not

identify any potentially interesting structure. More importantly, phylogenetic analysis with the five identified nematode antizymes failed to identify any conservation of primary RNA sequence (or for that matter potential secondary structure) outside of the core region that is shared between two or more members. This could indicate that no such extra *cis*-acting stimulators exist in nematode antizymes or that they are located in a very different place within the mRNA, for example the 3' untranslated region (the latter suggestion is not supported by our sequence analysis).

A common mechanism for frameshifting is re-pairing of the peptidyl tRNA in the new reading frame. However, an alternative mechanism whereby the peptidyl tRNA merely occludes the first base of the next codon, has been documented for yeast Ty3 frameshifting (Farabaugh *et al.*, 1993). Results of experiments with some mutants of the mammalian antizyme 1 shift site pointed to an occlusion mechanism (Matsufuji *et al.*, 1995). However, the mechanism with the wild-type, UCC-UGA, shift site is not clear. For *C.elegans* antizyme the UUU-UGA sequence would be an obvious candidate for a re-pairing since Phe-tRNA could pair perfectly with UUU in both frames. But with UCC-UGA the Ser-tRNA first reading UCC could at best pair two out of three with CCU. This important problem warrants further investigation.

The frameshift efficiency of *SPA* frameshift site is lower than that observed with mammalian antizyme 1 even when both are tested in the same organism (*S.pombe*) [for the frameshift efficiency of antizyme 1 cassette in *S.pombe*, see Ivanov *et al.* (1998c)]. It is possible that the observed efficiencies for *S.pombe* antizyme are artificially low because the constructs do not include all the *cis*-acting stimulatory elements. On the other hand there is no reason why a lower level of frameshifting does not correctly reflect the evolved balance with the other characteristics of the complex system such as relative protein stabilities.

Like other core cellular processes, the antizyme polyamine regulatory scheme is conserved from yeast *S.pombe* to human. It is not obvious why this very special mechanism is so exquisitely preserved over vast evolutionary time. Perhaps there is another whole aspect to the system that our experiments do not yet detect. From this viewpoint it would seem very important to exploit the genetics systems of *S.pombe* and *C.elegans* to understand more thoroughly the physiological effects of perturbing the antizyme system.

Materials and methods

DNA manipulation and sequencing

The *SPA* gene was amplified using the following primers: 5'-CAAACAAGTTTTTCATTATTGGTTTTTTTTAAATCAATCCCC (sense) and 5'-CGTAAATCCAATCTAAATTAATCTCAACTAAATCATGAAAAGCCTC (antisense). The *S.pombe* cDNA library used as a template in the amplification was kindly provided by R.Rowley (University of Utah). The *C.elegans* antizyme gene was amplified using the following primers: 5'-CCCAGGAATTCCTCGAGTATTTGAGTATAATTTTAC (sense) and 5'-CGGCCGCTCGAGTTAGACCTTGTAGCTCATGATG (antisense). This same amplified DNA was used to make the constructs for *in vitro* transcription and translation of *C.elegans* antizyme by cloning it into pTZ18U plasmid using the *SacI* and *HindIII* sites incorporated in the two primers. The in-frame construct was made using a two-step PCR. The cDNA sequences of *O.volvulus* and *P.pacificus* antizyme genes were obtained by performing 5' and 3'

RACE PCR with cDNA libraries, which were kindly provided by Ralf Sommer (*P.pacificus*) and Susan Haynes (*O.volvulus*). The *SPA* overexpression constructs were made by amplifying the gene with the primers 5'-GCATCCGAATTCCTCAATCCAAGCATCATACGCC (sense) and 5'-GCATCCGGATCCGCCAGTGTCTTACTTTGAGATGC (antisense), and then inserting *Bam*HI-digested product between the *MscI* and *Bam*HI sites of pREP3 plasmid. The in-frame construct was made by two-step PCR and subsequently all in-frame *SPA* constructs described below were made by one-step PCR using this plasmid's DNA as a template. To make the constructs for frameshift assays in *S.pombe*, DNA fragments with a given nucleotide length (as described in the main text), were amplified from both the *SPA* and *C.elegans* antizyme constructs described above. These fragments were then cloned between the *KpnI* and *Bst*EII sites of PIU-LAC plasmid (Ivanov *et al.*, 1998c). The PCR primers included an 'AC' spacer between the 5' cloning site (*Bst*EII) and the antizyme sequences in order to correct the reading frame. The *in vivo* frameshifting assays in *S.pombe* (strains *ura4-D18 leu1-32 ade6-M216 h⁻* and Δ *spa::LEU2 ura4-D18 leu1-32 ade6-M216 h⁻*) were done as described (Ivanov *et al.*, 1998c). The plasmid for *GST-SPA* expression was made by PCR amplifying *SPA* (all but the first codon of ORF1 through the downstream ORF2) from an in-frame template and cloning the product into the *EcoRI* and *XhoI* restriction sites of pGEX-5X-3 plasmid. The antizyme frameshift site in the BMV-coat-antizyme fusion construct (C3NE) (Matsufuji *et al.*, 1995) was mutated with a two-step PCR. To generate the two knockout strains, Δ *spa::URA4* and Δ *spa::LEU2*, both ORFs of *SPA* were replaced exactly with the ORF of either *URA4* or *LEU2*. To accomplish this, two pairs of primers amplified *URA4* and *LEU2* such that 50–60 nucleotides, which normally flank the two ORFs of *SPA*, flank the ORFs of the two genes. The amplified DNA products were gel purified and 2 μ g of each were used to electroporate into *ura4-D18 leu1-32 ade6-M216 h⁻* cells. *URA⁺* and *LEU⁺* transformants were selected by growth on *URA⁻* and *LEU⁻* media, respectively. PCR screen and partial sequencing, with primers flanking the regions used for the homologous recombination, confirmed the *SPA* disruptions. All DNA clones were sequenced with automated sequencing machines (ABI 100).

ODC antizyme assays

Schizosaccharomyces pombe ODC active crude extracts were prepared as follows: *S.pombe* (strain 1519, *leu1-32, h⁻*) provided by R.Rowley was grown to OD₆₀₀ 0.7 in 50 ml of minimal media + LEU. Ten milligrams of lysing enzymes (Sigma) were added, followed by continued incubation for 30 min at 30°C. Cells were harvested and washed once with cold homogenization buffer [25 mM Tris-HCl pH 7, 0.25 M sucrose, 1 mM dithiothreitol (DTT), 20 μ M pyridoxal-5-phosphate, 2 mM EDTA] then resuspended in 0.75 ml of homogenization buffer. Cells were broken open and the lysate was clarified by centrifugation at 10 000 r.p.m. for 15 min at 4°C. Extracts were dialyzed overnight in dialysis buffer (25 mM Tris-HCl pH 7.4, 1 mM DTT, 20 μ M pyridoxal-5-phosphate, 0.1 mM EDTA). A volume of 25 μ l of extract was used for each ODC assay. ODC activity was assayed by measuring the release of ¹⁴C₂ from L-[1-¹⁴C]ornithine (Amersham) as described (Nishiyama *et al.*, 1988). Each reaction took 1 h. Pre-incubation of *S.pombe* extract with 0.1 mM difluoromethyl ornithine (DFMO) for 15 min led to >99% inhibition of ¹⁴C₂ release.

Polyamine measurements

The cells were collected by centrifugation, washed twice with 1 ml of phosphate-buffered saline (PBS) and then the pellet was frozen at -80°C until use. The pellet was resuspended in 0.1 ml of PBS. An aliquot of the suspension was mixed with an equal volume of 8% perchloric acid, vortexed for 1 min, kept on ice for 5 min and centrifuged at 15 000 r.p.m., 4°C for 5 min. Ten microliters of the supernatant were subjected to polyamine analysis using fluorometry on high-performance liquid chromatography as described previously (Murakami *et al.*, 1989). Protein concentrations were determined with the BCA protein assay kit (Pierce).

In vitro transcription and translation

The experiments with the BMV-coat-antizyme fusion constructs were performed as described previously (Matsufuji *et al.*, 1995). All other plasmid DNA templates were prepared using QIAGEN Miniprep Kit and then digested with *HindIII*. Transcripts for *SPA in vitro* translation were made from PCR templates that had a T7 promoter incorporated into the PCR primers. Linearized DNA (1 μ g) was used as a template for *in vitro* transcription with Ambion MEGAscriptTM T7 Kit. The DNase-treated RNAs were recovered and resuspended in 40 μ l of RNase-free water. One microliter of each specified transcript suspension was used in

each *in vitro* translation reaction [0.5 μ l of 1 mM amino acid mix –Met, 7 μ l of reticulocyte lysate (Promega), 0.5 μ l of [³⁵S]Met (Amersham)] to a total volume of 10 μ l. The reactions were stopped by adding 1 μ l of RNase (10 mg/ml). The frameshift efficiencies were quantified as described (Ivanov *et al.*, 1998a).

Acknowledgements

We thank Roy Rowley for invaluable help with *S.pombe*. We thank Jasmine Parvaz and Rebecca Sharp for technical help. This work was supported by NIH Genetics Training Grant # 5T32GM07464-23 to I.P.I., Grants-in-Aid from the Japanese Ministry of Education, Science and Culture to Y.M. and S.M., Department of Energy grant DEFG03-99ER62732 to R.F.G. and NIH grant GM48152 to J.F.A.

References

Atkins,J.F., Böck,A., Matsufuji,S. and Gesteland,R.F. (1999) Dynamics of the genetic code. In Gesteland,R.F., Cech,T.R. and Atkins,J.F. (eds), *The RNA World*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2nd edn, pp. 637–673.

Auvinen,M., Paasinen,A., Andersson,L.C. and Hölttä,E. (1992) Ornithine decarboxylase is critical for cell transformation. *Nature*, **360**, 355–358.

Barnett,G.R., Seyfzadeh,M. and Davis,R.H. (1988) Putrescine and spermidine control degradation and synthesis of ornithine decarboxylase in *Neurospora crassa*. *J. Biol. Chem.*, **263**, 10005–10008.

Blaxter,M. (1998) *Caenorhabditis elegans* is a nematode. *Science*, **282**, 2041–2046.

Farabaugh,P.J., Zhao,H. and Vimaladithan,A. (1993) A novel programmed frameshift expresses the *POL3* gene of retrotransposon Ty3 of yeast: frameshifting without tRNA slippage. *Cell*, **74**, 93–103.

Fonzi,W.A. (1989) Regulation of *Saccharomyces cerevisiae* ornithine decarboxylase expression in response to polyamine. *J. Biol. Chem.*, **264**, 18110–18118.

Fredlund,J.O., Johansson,M.C., Dahlberg,E. and Oredsson,T.M. (1995) Ornithine decarboxylase and S-adenosylmethionine decarboxylase expression during the cell cycle of Chinese hamster ovary cells. *Exp. Cell Res.*, **216**, 86–92.

Gesteland,R.F., Weiss,R.B. and Atkins,J.F. (1992) Recoding: reprogrammed genetic decoding. *Science*, **257**, 1640–1641.

Heiskala,M., Zhang,J., Hayashi,S., Hölttä,E. and Andersson,L.C. (1999) Translocation of ornithine decarboxylase to the surface membrane during cell activation and transformation. *EMBO J.*, **18**, 1214–1222.

Heller,J.S., Fong,W.F. and Canellakis,E.S. (1976) Induction of a protein inhibitor to ornithine decarboxylase by the end products of its reaction. *Proc. Natl Acad. Sci. USA*, **73**, 1858–1862.

Ivanov,I.P., Gesteland,R.F. and Atkins,J.F. (1998a) A second mammalian antizyme: conservation of programmed ribosomal frameshifting. *Genomics*, **52**, 119–129.

Ivanov,I.P., Simin,K., Letsou,A., Atkins,J.F. and Gesteland,R.F. (1998b) The *Drosophila* gene for antizyme requires ribosomal frameshifting for expression and contains an intronic gene for snRNP Sm D3 on the opposite strand. *Mol. Cell. Biol.*, **18**, 1553–1561.

Ivanov,I.P., Gesteland,R.F., Matsufuji,S. and Atkins,J.F. (1998c) Programmed frameshifting in the synthesis of mammalian antizyme is +1 in mammals, predominantly +1 in fission yeast, but –2 in budding yeast. *RNA*, **4**, 1230–1238.

Ivanov,I.P., Gesteland,R.F. and Atkins,J.F. (1998d) Does antizyme exist in *Escherichia coli*? *Mol. Microbiol.*, **29**, 1521–1522.

Ivanov,I.P., Rohrwasser,A., Terreros,D.A., Gesteland,R.F. and Atkins,J.F. (2000) Discovery of spermatogenesis, stage specific, ornithine decarboxylase antizyme: antizyme 3. *Proc. Natl Acad. Sci. USA*, in press.

Koike,C., Chao,D.T. and Zetter,B.R. (1999) Sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cells. *Cancer Res.*, **59**, 6109–6112.

Lee,Y.B., Joe,Y.A., Wolff,E.C., Dimitriadis,E.K. and Park,M.H. (1999) Complex formation between deoxyhypusine synthase and its protein substrate, the eukaryotic translation factor 5A (eIF5A) precursor. *Biochem. J.*, **340**, 273–281.

Li,X. and Coffino,P. (1993) Degradation of ornithine decarboxylase: exposure of the C-terminal target by a polyamine-inducible inhibitory protein. *Mol. Cell. Biol.*, **13**, 2377–2383.

Li,X. and Coffino,P. (1994) Distinct domains of antizyme required for binding and proteolysis of ornithine decarboxylase. *Mol. Cell. Biol.*, **14**, 87–92.

Linden,M., Anehus,S., Langstrom,E., Baldetorp,B. and Heby,O. (1985) Cell cycle phase-dependent induction of ornithine decarboxylase-antizyme. *J. Cell Physiol.*, **125**, 273–276.

Matsufuji,S., Miyazaki,Y., Kanamoto,R., Kameji,T., Murakami,Y., Baby,T.G., Fujita,K., Ohno,T. and Hayashi,S. (1990) Analyses on ornithine decarboxylase antizyme mRNA with a cDNA cloned from rat liver. *J. Biochem.*, **108**, 365–371.

Matsufuji,S., Matsufuji,T., Miyazaki,Y., Murakami,Y., Atkins,J.F., Gesteland,R.F. and Hayashi,S. (1995) Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. *Cell*, **80**, 1360–1370.

Matsufuji,S., Matsufuji,T., Wills,N.M., Gesteland,R.F. and Atkins,J.F. (1996) Reading two bases twice: mammalian antizyme frameshifting in yeast. *EMBO J.*, **15**, 1360–1370.

Mitchell,J.L. and Wilson,J.M. (1983) Polyamine-stimulated alteration of the ornithine decarboxylase molecule in *Physarum polycephalum*. *Biochem. J.*, **214**, 345–351.

Mitchell,J.L.A., Judd,G.G., Bareyal-Leyser,A. and Ling,S.Y. (1994) Feedback repression of polyamine transport is mediated by antizyme in mammalian tissue-culture. *Biochem. J.*, **299**, 19–22.

Miyazaki,Y., Matsufuji,S. and Hayashi,S. (1992) Cloning and characterization of a rat gene encoding ornithine decarboxylase antizyme. *Gene*, **113**, 191–197.

Murakami,Y., Nishiyama,M. and Hayashi,S. (1989) Involvement of antizyme in stabilization of ornithine decarboxylase caused by inhibitors of polyamine synthesis. *Eur. J. Biochem.*, **180**, 181–184.

Murakami,Y., Matsufuji,S., Miyazaki,Y. and Hayashi,S. (1992a) Destabilization of ornithine decarboxylase by transfected antizyme gene expression in hepatoma tissue culture cells. *J. Biol. Chem.*, **267**, 13138–13141.

Murakami,Y., Matsufuji,S., Kameji,T., Hayashi,S., Igarashi,K., Tamura,T., Tanaka,K. and Ichihara,A. (1992b) Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. *Nature*, **360**, 597–599.

Murakami,Y., Matsufuji,S., Hayashi,S., Tanahashi,N. and Tanaka,K. (1999) ATP-dependent inactivation and sequestration of ornithine decarboxylase by the 26S proteasome are prerequisites for degradation. *Mol. Cell. Biol.*, **19**, 7216–7227.

Nishiyama,M., Matsufuji,S., Kanamoto,R., Takano,M., Murakami,Y. and Hayashi,S. (1988) Two-step purification of mouse kidney ornithine decarboxylase. *Prep. Biochem.*, **18**, 227–238.

Pegg,A.E. (1988) Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. *Cancer Res.*, **48**, 759–774.

Pegg,A.E. and McGill,S. (1979) Decarboxylation of ornithine and lysine in rat tissues. *Biochim. Biophys. Acta*, **568**, 416–427.

Persson,B.C. and Atkins,J.F. (1998) Does disparate occurrence of autoregulatory programmed frameshifting in decoding the release factor 2 gene reflect an ancient origin with loss in independent lineages? *J. Bacteriol.*, **180**, 3462–3466.

Rom,E. and Kahana,C. (1994) Polyamines regulate the expression or ornithine decarboxylase antizyme *in vitro* by inducing ribosomal frame-shifting. (Correction published in *Proc. Natl Acad. Sci. USA*, **91**, 9195.) *Proc. Natl Acad. Sci. USA*, **91**, 3959–3963.

Saito,T., Hascilowicz,T., Ohkido,I., Kikuchi,Y., Okamoto,H., Hayashi,S., Murakami,Y. and Matsufuji,S. (2000) Two zebrafish antizymes with different expression and activities. *Biochem. J.*, **345**, 99–106.

Sakata,K., Fukuchi-Shimogori,T., Kashiwagi,K. and Igarashi,K. (1997) Identification of regulatory region of antizyme necessary for the negative regulation of polyamine transport. *Biochem. Biophys. Res. Commun.*, **238**, 415–419.

Smith,R.C., Litwin,M.S. and Zetter,B.R. (1995) Identification of an endogenous inhibitor of prostatic carcinoma cell growth. *Nature Med.*, **1**, 1040–1045.

Suzuki,T., He,Y., Kashiwagi,K., Murakami,Y., Hayashi,S. and Igarashi,K. (1994) Antizyme protects against abnormal accumulation and toxicity of polyamines in ornithine decarboxylase-overproducing cells. *Proc. Natl Acad. Sci. USA*, **91**, 8930–8934.

Tabor,C.W. and Tabor,H. (1985) Polyamines in microorganisms. *Microbiol. Rev.*, **49**, 81–99.

Tome,M.E., Fiser,S.M., Payne,C.M. and Gerner,E.W. (1997) Excess putrescine accumulation inhibits the formation of modified eukaryotic

- initiation factor 5A (eIF-5A) and induces apoptosis. *Biochem. J.*, **328**, 847–854.
- Toth,C. and Coffino,P. (1999) Regulated degradation of yeast ornithine decarboxylase. *J. Biol. Chem.*, **274**, 25921–25926.
- Tsujii,T., Todd,R., Meyer,C., McBride,J., Liao,P.-H., Huang,M.-F., Chou,M.-Y., Donoff,R.B. and Wong,D.T.W. (1998) Reduction of ornithine decarboxylase antizyme (ODC-Az) level in the 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model. *Oncogene*, **16**, 3379–3385.
- Williams,K. (1997) Interactions of polyamines with ion channels. *Biochem. J.*, **325**, 289–297.
- Williams,L.J., Barnett,G.R., Ristow,J.L., Pitkin,J., Perriere,M. and Davis,R.H. (1992) Ornithine decarboxylase gene of *Neurospora crassa*: isolation, sequence and polyamine-mediated regulation of its mRNA. *Mol. Cell. Biol.*, **12**, 347–359.
- Zhu,C., Lang,D.W. and Coffino,P. (1999) Antizyme2 is a negative regulator of ornithine decarboxylase and polyamine transport. *J. Biol. Chem.*, **274**, 26425–26430.

Received January 4, 2000; revised and accepted March 7, 2000